Overview Olmesartan Medoxomil in Atherosclerosis Status: Completed Trial end date: 2006-02-01 Target enrollment: Participant gender: Summary This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured. Phase: Phase 3 Details Lead Sponsor: Sankyo Pharma GmbhTreatments: AtenololHydrochlorothiazideOlmesartanOlmesartan Medoxomil